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Nicotinic acetylcholine receptors (nAChR)2 are ligand-gated
ion channel neurotransmitter receptors. In mammals, they are
expressed as pentameric combinations of homologous subunits, translated from 16 different genes (␣1–␣7, ␣9, ␣10,
␤1–␤4, ␥, ␦, and ⑀). Functional diversity of nAChR is determined by subunit composition, producing nAChR subtypes
with overlapping pharmacological and biophysical characteristics (1).
␣4␤2*-nAChR are the most prevalent central nervous system
(CNS) nAChR subtype, comprising ⬇70% of all rodent CNS
nAChR (2) and are implicated in a wide range of normal and
pathological functions, including learning, memory, mood, and
nicotine dependence among others (3–17). ␣4␤2*-nAChR
functionally interact with nicotine at concentrations found in
smokers and are the target of varenicline, currently the most
successful smoking cessation pharmacotherapy (12, 13). Initial
studies suggested an (␣4)2(␤2)3 subunit stoichiometry for these
nAChR (18, 19). However, more recent work indicates that
both native and heterologously expressed ␣4␤2-nAChR can
exist in two isoforms with (␣4)2(␤2)3 and (␣4)3(␤2)2 subunit
stoichiometries, respectively, displaying high and (predominantly) low sensitivities (HS and LS) to activation by acetylcholine (ACh) (20 –25). The expression of ␣4␤2-nAChR isoforms
appears to be physiologically significant. For example, multiple epilepsy-associated ␣4 and ␤2 subunit mutants alter
ratios of HS to LS ␣4␤2-nAChR isoforms (17, 26), and agonists capable of preferentially stimulating LS ␣4␤2-nAChR
produce distinctive physiological effects (27–29). Accordingly, a better understanding of the respective roles of HS
and LS ␣4␤2*-nAChR isoforms is likely to have considerable
translational implications.
Agonist binding to nAChR is primarily driven by interactions
with a set of six peptide loops located at subunit interfaces.
Three (loops A–C) are contributed from the subunit on the
principal or (⫹)-side of the interface, with the remaining three
(loops D–F) being contributed from the subunit on the complementary or (⫺)-side of the interface. The (⫺)-side subunit is
oriented counterclockwise from the (⫹)-side subunit when
viewed from extracellular space (Fig. 1A) (20). A high degree of
conservation of critical agonist binding residues is seen across
2

The abbreviations used are: nAChR, nicotinic acetylcholine receptor; ACh,
acetylcholine; CRC, concentration response curve; HS, high sensitivity;
HSP, high sensitivity (pentameric concatemer); LS, low sensitivity; LS(P),
low sensitivity (pentameric concatemer); ANOVA, analysis of variance.

VOLUME 291 • NUMBER 5 • JANUARY 29, 2016

Downloaded from http://www.jbc.org/ at ELSEVIER BV on September 19, 2019

Two ␣4␤2 nicotinic acetylcholine receptor (␣4␤2-nAChR)
isoforms exist with (␣4)2(␤2)3 and (␣4)3(␤2)2 subunit stoichiometries and high versus low agonist sensitivities (HS and LS),
respectively. Both isoforms contain a pair of ␣4(ⴙ)/(ⴚ)␤2 agonist-binding sites. The LS isoform also contains a unique ␣4(ⴙ)/
(ⴚ)␣4 site with lower agonist affinity than the ␣4(ⴙ)/(ⴚ)␤2
sites. However, the relative roles of the conserved ␣4(ⴙ)/(ⴚ)␤2
agonist-binding sites in and between the isoforms have not been
studied. We used a fully linked subunit concatemeric nAChR
approach to express pure populations of HS or LS isoform
␣4␤2*-nAChR. This approach also allowed us to mutate individual subunit interfaces, or combinations thereof, on each isoform background. We used this approach to systematically
mutate a triplet of ␤2 subunit (ⴚ)-face E-loop residues to their
non-conserved ␣4 subunit counterparts or vice versa (␤2HQT
and ␣4VFL, respectively). Mutant-nAChR constructs (and
unmodified controls) were expressed in Xenopus oocytes. Acetylcholine concentration-response curves and maximum function were measured using two-electrode voltage clamp electrophysiology. Surface expression was measured with 125I-mAb
295 binding and was used to define function/nAChR. If the
␣4(ⴙ)/(ⴚ)␤2 sites contribute equally to function, making identical ␤2HQT substitutions at either site should produce similar
functional outcomes. Instead, highly differential outcomes
within the HS isoform, and between the two isoforms, were
observed. In contrast, ␣4VFL mutation effects were very similar
in all positions of both isoforms. Our results indicate that the
identity of subunits neighboring the otherwise equivalent
␣4(ⴙ)/(ⴚ)␤2 agonist sites modifies their contributions to
nAChR activation and that E-loop residues are an important
contributor to this neighbor effect.

Unequal ␣4(ⴙ)/(ⴚ)␤2 Nicotinic Receptor Agonist Site Effects
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We demonstrate that the contributions of ␣4(⫹)/(⫺)␤2 agonist-binding sites differ substantially within the HS isoform and
between the two different isoforms upon ␤2HQT substitution.
We further demonstrate that, unexpectedly, the ␣4VFL mutation produces very similar functional changes whether it is
inserted into the LS isoform-unique ␣4(⫹)/(⫺)␣4 agonistbinding site or not. Evidence for other allosteric effects of subunit (⫺)-face, E-loop, alterations also is obtained. These new
insights may provide further opportunities to develop compounds that pharmacologically distinguish between the isoforms and thus increase our understanding of each isoform’s
role in normal and disease physiology.

Experimental Procedures
Chemicals—Sazetidine-A and A-85380 were kindly provided
by Drs. Alan Kozikowski (University of Illinois, Chicago) and F.
Ivy Carroll (Research Triangle Institute, Research Triangle
Park, NC), respectively. All other reagents were purchased from
Sigma, unless noted otherwise.
Preparation of Unlinked ␣4␤2-nAChR Wild-type and Triple
Mutant E-loop cDNA Constructs—Unlinked nAChR human
wild-type (WT) ␣4 (CHRNA4; NCBI reference sequence designation NM_000744.6) or ␤2 (CHRNB2; NM_000748.2) subunit
cDNAs were transcriptionally optimized, synthesized, and
sequenced by GeneArt (ThermoFisher Scientific, Inc., Waltham, MA). Each subunit was subsequently excised from the
GeneArt shuttle vector with the restriction enzymes XbaI and
NotI and subcloned into a modified pCI expression vector containing an SwaI linearization site (vector was a gift from Dr.
Isabel Bermudez, Oxford Brookes University, Oxford, UK). The
unlinked triple mutant ␣4(H142V,Q150F,T152L) (␣4VFL) or
␤2(V136H,F144Q,L146T) (␤2HQT) subunit cDNAs were also
synthesized and sequenced by GeneArt as variants of their optimized WT parent subunits. These mutants were then subcloned into pCI as described previously.
Preparation of Concatemeric ␣4␤2-nAChR cDNA Constructs
Containing Wild-type and Triple Mutant E-loop Subunits—Dr.
Isabel Bermudez (Oxford Brookes University) provided a low
sensitivity pentameric (LSP) ␣4␤2-nAChR construct encoding
concatenated human nAChR subunits in the order ␤2-␣4-␤2␣4-␣4 (21). This construct, cloned into the previously mentioned modified pCI expression vector, served as the parent
plasmid for each of the concatemers engineered for this study.
This included the high sensitivity pentameric isoform (␤2-␣4␤2-␣4-␤2; HSP) ␣4␤2-nAChR construct (Fig. 1). The basic construction strategy has been described in detail elsewhere (21,
36). Briefly, all but the first ␤2 subunit were absent their start
codons and signal peptides, and all but the last were devoid of a
stop codon. Each subunit was tethered to its neighbor by a short
stretch of nucleotides encoding a series of 6 or 9 (Ala-Gly Ser)n
repeats, engineered to ensure a total linker length (including
the C-terminal tail of the preceding subunit) of 40 ⫾ 2 amino
acids. A unique set of six restriction sites either flanking the
entire concatemer or approximately bisecting each linker
between subunits was introduced along the pentamer sequence
(Fig. 1A). This permitted replacement of individual subunits (or
cassettes of multiple subunits if desired) using standard restriction digestion and ligation methods. GeneArt was used to
JOURNAL OF BIOLOGICAL CHEMISTRY
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subunits. This includes residues within interfaces that do not
harbor conventionally recognized canonical ␣(⫹)/(⫺)␤-type
agonist binding pockets (30 –34). Both ␣4␤2-nAChR isoforms
host a pair of canonical orthosteric, high affinity ␣4(⫹)/(⫺)␤2
agonist binding interfaces, but the LS (␣4)3(␤2)2 -nAChR isoform also contains a unique, non-canonical, ␣4(⫹)/(⫺)␣4 agonist-binding site (34 –36). This ␣4(⫹)/(⫺)␣4 site has lower
affinity for ACh or nicotine than the ␣4(⫹)/(⫺)␤2 site, making
it responsible for the intrinsically biphasic ACh concentrationresponse profile of the LS (␣4)3(␤2)2-nAChR isoform. This
complex CRC distinguishes it from the HS (␣4)2(␤2)3-nAChR
isoform, which lacks an ␣4(⫹)/(⫺)␣4 subunit interface and
produces monophasic CRCs (34 –36).
Activation of LS ␣4␤2-nAChR via interactions with a sufficiently high agonist concentration to engage all three binding
sites confers large increases in per receptor function compared
with the HS isoform ␣4␤2-nAChR, which can only be activated
by agonist binding at the common pair of ␣4(⫹)/(⫺)␤2 sites
(36). Importantly, activation of the HS phase of functional
responsiveness by LS (␣4)3(␤2)2-nAChR can occur just by targeting the common pair of ␣4(⫹)/(⫺)␤2 sites (either at agonist
concentrations too low to engage the ␣4(⫹)/(⫺)␣4 site or by
highly selective agonists that do not engage the ␣4(⫹)/(⫺)␣4
site at all). In this case, function per receptor closely resembles
that of the HS (␣4)2(␤2)3-nAChR isoform (34, 36, 37). Although
the ␣4(⫹)/(⫺)␣4 interface retains the typical features of an
nAChR agonist-binding site, it may therefore be thought of as
effectively potentiating the response as would a co-agonist or
positive allosteric modulator site (34 –36). These previous studies by ourselves and others have implicitly treated the two
canonical ␣4(⫹)/(⫺)␤2 agonist-binding sites as a functionally
equivalent pair. However, as illustrated in Fig. 1A, the nAChR
pentameric assemblies of each isoform are pseudosymmetrical;
the subunits that contribute the ␣4(⫹)/(⫺)␤2 agonist-binding
sites are surrounded by different neighbors. Because of this, it
seemed possible that the two canonical agonist-binding sites
might contribute differentially to activation (both within each
isoform and between the two isoforms).
To test this hypothesis, we used a concatemeric (linked subunit) nAChR approach. This allowed us to express pure populations of both HS and LS isoform ␣4␤2*-nAChR and to systematically mutate agonist-binding residues of ␣4(⫹)/(⫺)␤2
interfaces either individually or in combinations on either
background (Fig. 1). Unlike our previous study (36), we wished
to modify, not destroy, ligand binding at the targeted sites.
Therefore, we systematically altered triplets of ␤2 subunit (⫺)face E-loop residues to their non-conserved counterparts in the
␣4 subunit (␤2(V136H,F144Q,L146T); ␤2HQT) (Fig. 1B). This
can convert agonist binding at ␣4(⫹)/(⫺)␤2 sites to closely
resemble that at an ␣4(⫹)/(⫺)␣4 agonist-binding site (34, 38).
If our hypothesis is correct, then making equivalent E-loop
modifications in nominally equivalent ␣4(⫹)/(⫺)␤2 interfaces
should produce different outcomes. We also reciprocally
mutated ␣4 subunit (⫺)-face E-loop residues (␣4(H142V,
Q150F,T152L); ␣4VFL (34)) to examine the effects of this substitution inside, outside, or in the absence of an ␣4(⫹)/(⫺)␣4
interface, on both HS and LS backbones (Fig. 1C).

Unequal ␣4(ⴙ)/(ⴚ)␤2 Nicotinic Receptor Agonist Site Effects
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bovine, and rodent nAChR ␤2 subunits (41– 43). The protocol
used has previously been described (26, 36, 44). In brief, following determination of expressed nAChR function by maximal
stimulation (Imax, where Imax is peak current response) with
ACh (EC100, 1 s), sets of six oocytes each expressing individual
concatemeric ␣4␤2-nAChR isoforms or variants thereof were
sorted into a 24-well plate (one set per well). The accompanying
OR2 buffer was aspirated from each well and replaced with 2 nM
125
I-mAb 295 in OR2 (200 l), supplemented with 10% heatinactivated fetal bovine serum (to reduce nonspecific binding),
and incubated with gentle agitation for 3 h at 22 °C. Washing
was performed by aspiration of the radioactive solution and
replacement with OR2 supplemented with 10% heat-inactivated fetal bovine serum (2 ml, ice-cold). The oocytes were then
transferred to a fresh 24-well plate with the minimum possible
volume of diluted radioactive solution. This wash protocol was
repeated twice more. The thrice-washed oocytes were transferred to another fresh 24-well plate before being lysed overnight in 0.1% SDS, 0.01 N NaOH (0.5 ml), prior to scintillation
counting at 85% efficiency using a Packard TriCarb 1900 Liquid
Scintillation Analyzer (PerkinElmer Life Sciences). One or
more wells of non-injected oocyte controls were included per
assay plate to determine nonspecific binding. Nonspecific binding was subtracted from total binding determined in each of the
other wells of the same plate, to calculate specific binding.
Mean specific counts for sets of six HSP or LSP isoform-expressing oocytes were 885 and 469 cpm, respectively. This compared with mean nonspecific binding of 98 cpm per set of six
uninjected oocytes. Specific cell-surface binding of 125I-mAb
295 was converted to nAChR surface expression per oocyte
using the specific activity of the radioligand (initially 1150
Ci/mmol, but falling due to non-catastrophic decay of the
radiolabel) and by accounting for two antibody-binding sites
(two ␤2 subunits) per LSP isoform variant or three binding sites
(three ␤2 subunits) per HSP variant (Fig. 1). For each experiment, the resulting binding data (femtomoles of nAChR/
oocyte) were used to normalize Imax values (microamperes/
oocyte; calculated as the mean of the individually measured
Imax values obtained from the oocytes comprising the set of six
used in each binding determination) to microampere/fmol.
These specific function values were then compared among all
E-loop mutant concatemers and to the non-E-loop mutant LSP
and HSP controls.
Data Analysis—Log10 EC50 values were determined from
individual CRCs by non-linear least squares curve fitting (Prism
5.0; GraphPad Software, Inc., La Jolla, CA). Unconstrained
monophasic or biphasic logistic equations were used to fit all
parameters, including Hill slopes and fractional contributions
of function attributable to HS or LS nAChR, where applicable.
A sum-of-squares F-test was used to verify when data were
better fit by the biphasic rather than monophasic model. Note
that precision in determining ACh log10 EC50 values from
biphasic CRCs (S.E. in log10 EC50 values between 0.1 and 0.35) is
substantially lower than for monophasic CRCs (log10 EC50 S.E.
values ⱕ0.07). One-way analysis of variance (ANOVA) and
Bonferroni’s multiple comparison tests were used to compare
functional parameters across ␣4␤2-nAChR variants (Prism 5.0
or SigmaPlot Version 12.5, Systat Software Inc., San Jose, CA).
VOLUME 291 • NUMBER 5 • JANUARY 29, 2016
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design, synthesize, and sequence-verify optimized WT and
mutant subunits for substitution into the parent construct.
These new subunits were variants of the unlinked optimized
subunits previously described, with the addition of the flanking
AGS-repeat linkers and restriction sites required for correct
placement within the resulting new pentameric concatemers. A
unique restriction site was also introduced into each synthetic
mutant sequence destined for ligation within a concatemer.
This allowed for unambiguous verification of every new
construct.
RNA Preparation and Oocyte Injection—As described previously (36), both unlinked and concatenated plasmid cDNA constructs were SwaI-linearized, proteinase K-treated, column-purified, and transcribed into cRNA (mMessage mMachine T7
kit, Ambion, ThermoFisher Scientific, Waltham, MA). Each
cRNA sample was DNase I-treated, column-cleaned, and gelanalyzed for size and quality. Stage V/VI Xenopus laevis
oocytes, purchased from Ecocyte LLC (Austin, TX), were
injected with biased ratio combinations of mRNAs encoding
unlinked subunits (1 or 10 ng) or with 20 ng of mRNA encoding
a concatemeric construct. Injected oocytes were incubated at
13 °C for 6 –10 days before testing.
Two-electrode Voltage Clamp Electrophysiology—Methodology for obtaining CRCs and maximal current responses from
nAChR-injected oocytes has been published elsewhere (36, 39,
40). Briefly, at least 6 days post-injection, oocytes were voltageclamped at ⫺70 mV with an Axoclamp 900A amplifier (Molecular Devices, Sunnyvale, CA). Recordings were sampled at 10
kHz (low pass Bessel filter, 40 Hz; high pass filter, direct current), and the traces were extracted and analyzed using Clampfit software (Molecular Devices). Any oocytes with leak currents ⬎50 nA were discarded. Drugs were applied at a flow rate
of 4 ml min⫺1 using a 16-channel, gravity-fed perfusion system
with automated valve control (AutoMate Scientific, Inc., Berkeley, CA) in OR2 buffer (NaCl, 82.5 mM; KCl, 2.5 mM; MgCl2, 1
mM, HEPES 5 mM, pH 7.6) at 22 °C. Solutions were supplemented with atropine sulfate (1.5 M) to block any muscarinic
responses. Agonists were acutely perfused for 1 s with a 60-s
washout between drug applications. In CRC analyses requiring
a 5-min sazetidine-A (3.16 nM) pretreatment, both ACh and
wash applications contained the same concentration of sazetidine-A. All concentration-response recording sessions included oocytes injected with non-mutant HSP and LSP concatemer controls (minimum of three oocytes per group) to
account for day-to-day and batch-to-batch variability in functional expression levels.
125
I-mAb 295 Labeling of X. laevis Oocyte Surface nAChR
Populations—Introduction of any mutation could potentially
alter surface expression of the host nAChR. Any such changes
would have corresponding effects on functional expression,
independent of effects on function per receptor. Surface
expression levels of each concatenated ␣4␤2-nAChR isoform,
and variant thereof, were quantified with 125I-mAb 295 in an
oocyte binding assay. For consistency, the entire family of either
LSP or HSP triple E-loop mutants was tested on the same day.
LSP and HSP controls (containing no E-loop mutant subunits)
were included in every experiment. mAb 295 is a monoclonal
antibody that specifically recognizes correctly folded human,

Unequal ␣4(ⴙ)/(ⴚ)␤2 Nicotinic Receptor Agonist Site Effects

Results
Acetylcholine Concentration-Response Curves Generated
from the ␤2HQT Chimeric E-loop Subunit Introduced into
Either LS- or HS-based ␣4␤2-nAChR Concatemers Reveal Position-, Copy-, and Isoform-specific Effects—As noted in the
Introduction, the account describing how HS phase function
arises in either LS or HS isoform ␣4␤2-nAChR (34, 36) contains
an implicit assumption. This is that the two ␣4(⫹)/(⫺)␤2 agonist-binding sites found in both isoforms (see Fig. 1A) are functionally equivalent (both to each other in a given pentameric
backbone, and between HS and LS ␣4␤2-nAChR isoforms).
Fully linked pentameric constructs provide the ability to substitute E-loop mutant subunits at any chosen position or combination of positions in HS or LS isoform ␣4␤2-nAChR. Using
these concatemeric constructs, we were therefore able to sysJANUARY 29, 2016 • VOLUME 291 • NUMBER 5

tematically test this assumption for the first time, by introducing the ␤2HQT E-loop mutant (located on the (⫺)-side of the
␤2 subunit) into defined positions within LSP and HSP ␣4␤2nAChR (Fig. 1B). The resulting family of constructs represents
every possible permutation of the ␤2HQT triple mutant subunit cloned into the WT LSP and HSP parent constructs.
In the case of the LSP-based constructs, substitution of the
(⫺)␣4-like ␤2HQT mutant subunit into either of the ␣4(⫹)/
(⫺)␤2 agonist-binding sites (transforming the interface into
something resembling the lower affinity ␣4(⫹)/(⫺)␣4 interface) abolished HS component function (Fig. 2A). The same
was true when ␤2HQT substitution was performed at both
␣4(⫹)/(⫺)␤2 sites. The resulting monophasic CRCs produced
by the three mutant LSP constructs had very similar log10 EC50
values to each other (EC50 ⬇230 M) and were approximately
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 1. Schematic illustration of E-loop chimera construction using concatenated LS (␣4)3(␤2)2 and HS (␣4)2(␤2)3 isoforms of nAChR. A, top, diagram
representing the linked LSP and HSP ␣4␤2-nAChR isoforms. Illustrated are subunit positions and agonist binding pockets (filled circles and triangle) formed
from a principal (⫹) and E-loop-containing complementary (⫺)-face as observed from extracellular space. This convention is used in subsequent figure
captions to indicate the positions of agonist binding pockets within parent constructs for concatemer series harboring one or more mutant subunits. Also
shown are typical responses to a range of ACh concentrations for these two isoforms (LSP 10⫺7.5 to 10⫺4 M; HSP 10⫺7.5 to 10⫺5 M), performed on day 6
post-injection. Traces for mutant variants of these two parent constructs showed very similar waveforms, other than in terms of peak current magnitude.
Bottom, at the cDNA level, individual subunits within the LSP or HSP backbone are tethered by linkers encoding AGS repeats. Linkers are bisected by unique
restriction sites that allow rapid substitution of one or more E-loop mutant-containing counterparts. B, a series of 10 concatemers was constructed from either
the LSP (left panel) or HSP (right panel) WT parent by cloning one, two, or three copies of the ␤2 subunit hosting the non-identical ␣4-equivalent E-loop residues
H136Q144T146 (␤2HQT (34)). Each mutant ␤2 subunit is highlighted in dark blue and boldface with the chimeric ␣4 E-loop-containing (⫺)-face depicted by an
orange semicircle. Note that open symbols represent altered ligand-binding sites. C, 10 additional concatemers were constructed with the reciprocal ␤2 E-loop
residues placed in one, two, or three copies of ␣4 subunits. The V142F150L152 (␣4VFL) subunit is labeled and arranged as in B using contrasting colors.

Unequal ␣4(ⴙ)/(ⴚ)␤2 Nicotinic Receptor Agonist Site Effects
TABLE 1
Effects of introducing ␤2HQT E-loop mutant subunits into the LSP and
HSP ␣4␤2 nAChR concatemer backgrounds (ACh CRCs)

FIGURE 2. ACh concentration-response profiles for the ␤2HQT E-loop
mutant series of concatenated LS and HS ␣4␤2-nAChR isoforms. A,
oocytes expressing concatenated LSP constructs incorporating one or two
copies of the ␤2HQT E-loop mutant subunit (position(s) indicated by ␤2m)
were acutely stimulated with the indicated range of ACh concentrations. All
three mutant concatemers generated similar monophasic CRCs lacking the
HS component seen in WT LSP. B, seven-member HSP family of ␤2HQT E-loop
mutant concatemers generated three classes of CRCs ranging from no ACh
affinity change for single copy position 3 or 5 constructs to a biphasic
response for single copy position 1 and finally to LS-like for each of the double
and triple copy versions. Choice of fitting each CRC to either a one- or two-site
unconstrained logistic model was made using the extra sum-of-squares
F-test. Details of the obtained pharmacological parameters and the statistical
analysis used to compare results are provided in Table 1. Data points represent the mean (⫾S.E.) of at least four oocytes (numbers provided in Table 1).
CRCs obtained using wild-type LSP (f) and HSP (‚) parent constructs are
included in both graphs for ease of comparison within and between isoforms.

one-half log unit higher than the estimated log10 EC50 value for
the LS component of LSP control (EC50 ⬇60 M; Fig. 2A, Table
1). In summary, ␤2HQT substitution effects on ␣4␤2-nAChR
LSP isoform function were both position- and copy numberindependent; in every case the resulting function was purely LS
component-like.
In striking contrast to the LSP series, the HSP-derived family
of ␤2HQT-containing concatemers generated a complex set of
CRCs that could be classified into three groups (Fig. 2B). The
first group consisted of two concatemers hosting a single copy
of ␤2HQT at positions 3 or 5, which yielded HS log10 EC50
values indistinguishable from that of the unmutated HSP control (EC50 ⬇2 M; Table 1). Note that the ␤2HQT subunit in
position 3 is part of an ␣4(⫹)/(⫺)␤2 binding pocket, although
that in position 5 is not (Fig. 1B). In other words, these constructs had one (␤2HQTp3) or no (␤2HQTp5) ␣4/␤2 interfaces

2448 JOURNAL OF BIOLOGICAL CHEMISTRY

††† One-way ANOVA determined significant differences among the log10 EC50
values derived from LSP background CRC data (including those measured for
the biphasic response of the unmodified LSP control construct; F12,63 ⫽ 21.29,
p ⬍ 0.0001). Post hoc comparisons were performed using the Bonferroni correction, and showed that the low-sensitivity phase of un-modified (control) LSP
responses had an log10 EC50 value significantly different to that of the control
high-sensitivity phase response of the same construct. Further, the log10 EC50
values of the monophasic responses of all three LSP ␤2HQT mutant constructs
were also significantly different from that of the HS-phase control response, but
indistinguishable from each other and that of the low-sensitivity phase response
of the control construct: the difference of this group of LS-like responses from
the control HS-phase response is denoted as †, p ⬍ 0.001.
*** One-way ANOVA identified significant differences across the log10 EC50 values calculated from the HSP-background CRCs (including that obtained from
the unmodified HSP control construct; F14,92 ⫽ 17.33, p ⬍ 0.0001). Post hoc
comparisons were performed using the Bonferroni correction and again
showed that the log10 EC50 values could be divided into two groups (one indistinguishable from that of the monophasic HS phase response of the nonmutant HSP control, and a second with significantly lower ACh potency; all
values in the LS phase group were statistically indistinguishable from each
other). The difference of the LS-like group log10 EC50 values from those of
the HS-like group is noted as ***, p ⬍ 0.001. Extra sum-of-squares F test for
a biphasic model preferred over a monophasic model: a, F(DFn ⫽ 6,DFd ⫽ 100) ⫽
19.95; p ⬍ 0.0001; b, F(DFn ⫽ 3,DFd ⫽ 86) ⫽ 19.95; p ⬍ 0.0003.

converted to a mock ␣4(⫹)/(⫺)␣4 interface, retaining one or
both natural ␣4(⫹)/(⫺)␤2 interfaces, respectively.
The second HSP mutant group had just one member, the
HSP concatemer containing a single ␤2HQT subunit at position 1. This ␤2HQTp1 construct also had one ␣4(⫹)/(⫺)␤2to-mock ␣4(⫹)/(⫺)␣4 interface conversion but, like the
␤2HQTp3 mutant, preserved one ␣4(⫹)/(⫺)␤2 interface. This
concatemer was the only HSP ␤2HQT mutant construct that
generated a biphasic ACh CRC. The observed HS and LS phase
EC50 values for this construct (⬇1.8 and ⬇60 M, respectively)
were indistinguishable from those of the LSP control (⬇2.8 and
⬇60 M; Table 1). This biphasic response was so striking that it
was further confirmed using two highly HS versus LS isoformselective nicotinic agonists, A-85380 and the structurally
VOLUME 291 • NUMBER 5 • JANUARY 29, 2016
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Oocytes were injected with RNA encoding concatenated LSP or HSP ␣4␤2-nAChR
constructs containing zero (LSP or HSP controls in boldface), one, or more copies of
the ␤2HQT subunit at the position (s) shown in blue type. TEVC recording of
agonist perfused oocytes was used to establish ACh CRCs (Fig. 2, “Experimental
Procedures”). Least squares curve fitting was used to determine ACh log10 (M) ⫾ S.E.
values. Data were fit to an unconstrained monophasic logistic model, unless data
were better fit to a biphasic logistic model (determined using the extra sum-ofsquares F-test). For biphasic fits, ACh log10 (M) EC50 ⫾ S.E. values were estimated for
both LS and HS phases, and the fractional HS component of the biphasic response
also was estimated. The number of individual oocytes is designated (n; typically for
2– 4 oocytes per individual test). Since data were collected on a single day for the
complete set of mutants on either the LSP or HSP backbone (see “Experimental
Procedures”), including all ␤2HQT and ␣4VFL mutant constructs, one-way
ANOVA was applied to determine significant differences between all log10 EC50
values collected on the LSP backbone, and a second analysis was performed on the
full set of log10 EC50 values collected on the HSP backbone. In addition, data representing ACh-activated maximal function (Imax in nA, rounded to 1 or 2 significant
digits) and Imax values corrected for surface nAChR (microampere/fmol) were generated from (N) experiments testing 6 individual oocytes per concatemer per experiment (See Figs. 4 and 5 for these data shown relative to and compared with those
derived from control LSP and HSP concatemers, respectively). All current amplitude-based data are means ⫾ S.E.

Unequal ␣4(ⴙ)/(ⴚ)␤2 Nicotinic Receptor Agonist Site Effects

related compound sazetidine-A. A-85380 demonstrates an
unusually high degree of agonist selectivity between HS and LS
isoform ␣4␤2-nAChR (24, 36, 45). In response to acute
A-85380 stimulation, the HSP ␤2HQT position 1 construct
generated a clearly biphasic CRC with an ⬃1:1 distribution of
HS and LS components (Fig. 3), confirming the initial observation of a biphasic ACh CRC. Sazetidine-A (46) activates only HS
isoform ␣4␤2-nAChR with high efficacy (47) and may be used
to selectively occupy (36, 37) and inactivate (by desensitization)
responses arising from ␣4(⫹)/(⫺)␤2 interfaces (36). A desensitizing concentration of sazetidine-A (3.16 nM (36)) was used
to pretreat oocytes expressing the HSP ␤2HQT position 1 concatemer prior to acute A-85380 exposure. This led to complete
suppression of the HS portion of the response, confirming that
the resulting CRC must arise from A-85380 activity at the
remaining ((position 4) ␣4(⫹)/(⫺)␤2 (position 3)) interface left
within the position 1 HSP ␤2HQT construct.
The third group of HSP mutants consisted of all concatemers
containing two copies of the ␤2HQT E-loop, plus that with all
three positions mutated to the ␤2HQT (Fig. 2B and Table 1). All
three doubly substituted constructs produced log10 EC50 values
indistinguishable from each other or from that of the LS phase
of unmutated LSP ␣4␤2-nAChR (EC50 ⬇60 M). Interestingly,
even a combination of ␤2HQT subunits placed in positions 3
and 5 (neither of which had any effect individually) resulted in
loss of all HS phase function. The EC50 value for the triple
␤2HQT mutant HSP (⬇190 M) was like that of ␤2HQT
mutants introduced into the LSP backbone (Fig. 2A and Table
1). Thus, in complete contrast to the effects of ␤2HQT mutant
subunit incorporation on LSP ␣4␤2-nAChR, effects in HSP
␣4␤2-nAChR constructs were strongly influenced both by
position and by copy number. Most importantly, effects on
ACh CRC responses were radically different between the two
constructs in which a single ␤2HQT mutant subunit was placed
in either of the two nominally identical ␣4(⫹)/(⫺)␤2 agonist
binding pockets.
JANUARY 29, 2016 • VOLUME 291 • NUMBER 5
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FIGURE 3. Sazetidine-A pretreatment abolishes HS component function
in oocytes expressing the ␤2HQT position 1 HSP concatemer. Acute
responses to the indicated range of A-85380 concentrations were measured
before and after a 5-min pretreatment with 3.16 nM sazetidine-A in the ␤2HQT
position 1 HSP concatemer. Without pretreatment, despite mutating one of
the canonical ␣4(⫹)/(⫺)␤2 interfaces, a significant fraction of HS function
was retained in this construct. A-85380 generated a strongly biphasic CRC
(log10 EC50 HS ⫽ ⫺7.64 ⫾ 0.04, log10 EC50 LS ⫽ ⫺5.04 ⫾ 0.04, and fractional
HS contribution ⫽ 0.51 ⫾ 0.02). This CRC became monophasic (LS-only) following a desensitizing treatment with sazetidine-A (log10 EC50 ⫽ ⫺5.09 ⫾
0.05). n ⫽ 4 oocytes per treatment. Note the inset that shows the location of
the subunits carrying the mock ␣4(⫹)/(⫺)␣4 interface surrounded by WT ␤2
neighbors which, among all of the mutant constructs generated in this study,
uniquely mimics the structure of the unmutated LSP construct.

ACh-induced Function Per Surface-expressed LS or HS ␣4␤2nAChR Concatemer Reveals Position-, Copy-, and Isoform-specific Effects of ␤2HQT Chimeric E-loops—In addition to exploring effects of ␤2HQT substitution at defined subunit positions
on agonist activation affinities, we also wanted to assess effects
on amounts of nAChR function. We previously have shown
that cell surface levels of HSP and LSP ␣4␤2-nAChR isoforms
in oocytes injected with equivalent levels of pentamer cRNA are
comparable (36). This indicated that the observed differences
in amount of HSP versus LSP function were almost exclusively
due to differences in function per surface-expressed nAChR; i.e.
due to the intrinsic properties of the ␣4␤2-nAChR isoforms.
We have also shown that introducing mutations at subunit
interfaces can significantly affect surface expression of the
resulting nAChR constructs (36). Accordingly, we normalized
function to the amount of nAChR surface expression (measured using ␤2-specific monoclonal antibody binding).
For the LSP ␤2HQT mutant constructs, measurements of
maximum ACh-induced function (Imax) alone showed significant losses of function for both the position 1-only and double
mutant ␤2HQT mutant constructs, reducing Imax to a level
resembling that of the unmutated HSP control construct (Fig.
4A). The LSP position 3-only ␤2HQT mutant construct, in contrast, produced an unchanged Imax value compared with the
unmutated LSP construct. However, as shown in Fig. 4B, surface expression of all three LSP ␤2HQT mutant constructs was
significantly suppressed by incorporation of the mutant subunit(s). When we compensated for this effect (Fig. 4C), it
became apparent that function of both single mutant LSP
␤2HQT mutant constructs was significantly increased, to
approximately double that of the unmutated LSP control, on a
per nAChR basis (Table 1). Also, on a per nAChR basis, function of the position 1 ⫹ 3 double LSP ␤2HQT mutant construct
was statistically similar to that of the unmutated LSP ␣4␤2nAChR construct (Fig. 4C and Table 1). As in the case of log10
EC50 values (Fig. 2A), ␤2HQT-mediated functional enhancement in LSP was position-independent. However, copy number
did affect the per nAChR amount of function, unlike effects on
agonist log10 EC50 values that were the same regardless of
whether one or both positions contained ␤2HQT mutant subunits (Fig. 2A).
The family of HSP ␤2HQT concatemers again revealed a
more complicated response to incorporation of mutant subunits (Fig. 5 and Table 1). The single copy ␤2HQT position 1
construct (the only ␣4␤2 HSP mutant to produce a biphasic
CRC; Fig. 2B) exhibited significantly lower surface expression
and Imax. On a per nAChR basis, these effects combined to
produce an apparent, but not-quite-significant, reduction in
per nAChR function. In contrast, the position 3-only ␤2HQT
mutant (which did not affect the ACh concentration-response
outcome; Fig. 2B) significantly increased Imax compared with
the unmutated HSP control, while having no effect on surface
expression. On a per nAChR basis, this resulted in a statistically
significant doubling of function. Although the non-agonistbinding interface position 5 ␤2HQT single mutant HSP construct showed a modest but marginally significant increase in
Imax compared with the non-mutant HSP control, this did not
quite retain significance on a per nAChR basis. Neither did this
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0.001; C, F12,63 ⫽ 36.56; p ⬍ 0.001. Post hoc comparisons were performed
in each case using the Bonferroni correction; differences from the unmutated LSP control are noted as follows: **, p ⬍ 0.01; ***, p ⬍ 0.001.
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FIGURE 4. ␤2HQT E-loop mutation effects on peak ACh-induced function
(Imax) and nAChR surface expression within LSP concatemers. Oocytes
expressing concatenated LSP constructs incorporating one or two copies of
the ␤2HQT E-loop mutant subunit were screened for maximal ACh current
responses, followed by 125I-mAb 295 binding to determine femtomoles of
surface nAChR (assuming two ␤2-binding sites per LSP and three per HSP
construct, see “Experimental Procedures”). All results, including the WT HSP
control, were normalized to the unmutated LSP concatemer for at least four
individual experiments (denoted with a dashed horizontal line in each panel;
see Table 1 for non-normalized data and number of replicates/experiments
performed). A, Imax was reduced ⬃4-fold (close to HSP levels) for the LSP
constructs harboring ␤2HQT mutations in position 1 or positions 1 ⫹ 3,
although the position 3 variant was unchanged. B, surface nAChR expression
levels were reduced 50 –75% across all three LSP ␤2HQT mutant constructs.
Note that the unmutated HSP construct had a similar level of surface expression as that of the unmutated LSP construct, confirming our earlier finding
(36). C, Imax values were normalized to amounts of nAChR surface expression
for each LSP ␤2HQT mutant concatemer. Function per surface nAChR was
increased ⬃2-fold for each of the single position LSP mutants, whereas the
double position variant had WT levels of function. HSP typically produced
⬃10% of LSP-mediated function per receptor in this study. Because data were
collected for the complete set of mutants on the LSP backbone in each individual experiment (see “Experimental Procedures”), including all ␤2HQT and
␣4VFL mutant constructs, one-way ANOVA was applied to determine significant differences within the sets of Imax, surface expression, or function per
receptor values collected on the LSP backbone. One-way ANOVA determined that significant differences existed between LSP backbone groups
in each panel as follows: A, F12,77 ⫽ 57.23; p ⬍ 0.001; B, F12,63 ⫽ 5.69; p ⬍

position 5-only mutant construct produce any effect on ACh
concentration-response (Fig. 2B). Interestingly, per nAChR
function of two of the HSP double-␤2HQT mutant constructs
(positions 1 ⫹ 3 and 3 ⫹ 5) did not significantly differ from that
of HSP control. However, when the position 1 ␤2HQT subunit
was included with the off-interface position 5 ␤2HQT subunit,
in either the double and triple mutant configurations (e.g. positions 1 ⫹ 5, or positions 1 ⫹ 3⫹5), there was a highly significant, ⱖ60%, reduction in function per nAChR. To summarize,
position- and copy-dependent ␤2HQT mutant subunit effects
on per nAChR function again exposed asymmetries between
the nominally similar ␣4(⫹)/(⫺)␤2-binding sites within the
HSP ␣4␤2-nAChR isoform.
Acetylcholine Concentration-Response Curves and per
nAChR Function of LS and HS nAChR Concatemers Reveal
Symmetrical and Copy-dependent Effects of ␣4VFL Chimeric
E-loop Subunit Introduction—In addition to the just-explored
␣4(⫹)/(⫺)␤2 agonist-binding sites common to HSP and LSP
␣4␤2-nAChR, we also wished to specifically target the unique
␣4(⫹)/(⫺)␣4 interface present between positions 4 and 5
within the LSP (Fig. 1A, left panel). A previous study (34) had
addressed this question using unlinked ␣4VFL mutant subunits. However, the unlinked subunit approach altered all three
␣4 subunits in the ␣4␤2-nAChR LS isoform. In contrast, use of
concatemeric constructs allowed us to assess effects of ␣4VFL
mutant incorporation at each available position, either singly or
in combination (see Fig. 1C).
Unexpectedly, CRCs obtained from the family of ␣4␤2nAChR LSP ␣4VFL-containing constructs were uniformly
monophasic (Fig. 6A). This was true whether single or multiple
positions were substituted and was independent of which position(s) was altered. Even the three LSP variants where the
␣4(⫹)/(⫺)␣4 interface E-loop was not mutated (␣4VFL in positions 2, 5, or 2 ⫹ 5; see Fig. 1C) displayed the same outcome.
Even more surprisingly, statistically indistinguishable EC50 values (between 7 and 12 M) were obtained from all of the LSP
␣4VFL mutant constructs; these EC50 values were intermediate
between those of the HS (0.6 M) and LS (⬇60 M) phases of
unmutated LSP function (Fig. 6A and Table 2). This was true
even though there was no change in numbers of ␣4(⫹)/(⫺)␤2
or ␣4(⫹)/(⫺)␣4 interfaces or even when the ␣4(⫹)/(⫺)␣4
interface was replaced by an additional mock ␣4(⫹)/(⫺)␤2
interface. In summary, effects of the ␣4VFL E-loop mutant
were completely independent of position and copy number in
the LSP ␣4␤2-nAChR isoform. A very similar outcome was
observed when introducing ␣4VFL mutant subunits into the
␣4␤2-nAChR HSP isoform (where none of the mutant subunits
could be introduced into an agonist binding pocket; see Fig.
1C). In every case, CRCs of ␣4VFL HSP mutant constructs
remained identical to that of the non-mutant HSP control
(EC50 ⬇2 M; Fig. 6B and Table 2).
Although the agonist-pharmacology effects of ␣4VFL
mutant subunit incorporation into LSP ␣4␤2-nAChR were
position- and copy number-independent, this was not the case
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for effects on function per receptor (Fig. 7). As shown in Fig. 7A,
Imax values were significantly reduced for all ␣4VFL mutant
LSP constructs. Qualitatively, the reduction of Imax values
increased progressively from single- to double- to triple-substituted LSP constructs (Fig. 7A). Interestingly, reductions in Imax
for each of the three single-substituted constructs were largely
accounted for by loss of surface expression (Fig. 7B); no changes
in per nAChR function compared with the unmutated LSP
␣4␤2-nAChR control were measured for any of the single
␣4VFL-substituted constructs (Fig. 7C and Table 2). However,
all three of the double ␣4VFL-substituted LSP constructs produced significantly less per nAChR function compared with the
were performed in each case using the Bonferroni correction; differences
from the unmutated LSP control are noted as follows: *, p ⬍ 0.05; **, p ⬍ 0.01;
***, p ⬍ 0.001.
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FIGURE 5. ␤2HQT E-loop mutation effects on peak ACh-induced function
(Imax) and nAChR surface expression within HSP concatemers. Oocytes
expressing concatenated HSP constructs incorporating one, two, or three
copies of the ␤2HQT E-loop mutant subunit were screened for maximal ACh
current responses, followed by 125I-mAb 295 binding to determine surface
nAChR expression (accounting for three ␤2-binding sites per HSP construct,
see “Experimental Procedures”). All results were normalized to the unmutated HSP concatemer for at least three individual experiments (denoted with
a dashed horizontal line in each panel; see Table 1 for non-normalized data
and number of experiments performed). A, Imax was reduced ⬃90% for the
four HSP constructs harboring ␤2HQT mutations in position 1, although the
single position 3 and 5 variants significantly increased peak current. There
was no detectable change for the position 3 ⫹ 5 variant. B, surface nAChR
expression levels were reduced ⬇75% in three of the four HSP ␤2HQT position 1-containing mutants, although the remaining four mutant concatemers
had control levels of surface expression. C, function per surface nAChR was
increased ⬃2-fold only for the single position 3 HSP mutant, whereas two of
the constructs hosting ␤2HQT in positions 1 ⫹ 3 or 1 ⫹ 3 ⫹ 5 showed significant reductions compared with WT. The remaining four constructs showed
no significant changes versus control HSP. Because data were collected for the
complete set of mutants on the HSP backbone in each individual experiment
(see “Experimental Procedures”), including all ␤2HQT and ␣4VFL mutant constructs, one-way ANOVA was applied to determine significant differences
within the sets of Imax, surface expression, or function per receptor values
collected on the HSP backbone. One-way ANOVA determined that significant
differences existed between groups in each panel: A, F11,36 ⫽ 65.38; p ⬍ 0.001;
B, F11,33 ⫽ 9.1; p ⬍ 0.001; C, F11,32 ⫽ 19.9; p ⬍ 0.001. Post hoc comparisons

FIGURE 6. ACh concentration-response profiles for the ␣4VFL E-loop
mutant series of concatenated LS and HS isoforms of ␣4␤2 nAChR. A,
oocytes expressing concatenated LSP constructs incorporating one, two, or
three copies of the ␣4VFL E-loop mutant subunit (position(s) indicated by
␣4m) were acutely stimulated with the indicated range of ACh concentrations. CRCs generated from all seven mutant constructs were monophasic
with nearly identical EC50 values, which were intermediate between the HS
and LS phases of the biphasic unmutated LSP construct CRC. B, HSP set of
three ␣4VFL E-loop mutant single or double copy concatemers generated
CRCs that were indistinguishable from the HSP control. Data points represented the mean (⫾S.E.) of at least three oocytes and were fit to unconstrained, one-, or two-site logistic equations (most appropriate assignment
determined using the extra sum-of-squares F-test). Details of the pharmacological parameters calculated and of the applied statistical analyses are
reported in Table 2. CRCs obtained from unmodified LSP (f) and HSP (‚)
parent constructs are included in both graphs for ease of comparison within
and between isoforms.
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TABLE 2
Effects of introducing ␣4VFL E-loop mutant subunits into the LSP and
HSP ␣4␤2 nAChR concatemer backgrounds (ACh CRCs)

Oocytes injected with cRNA encoding concatenated LSP or HSP ␣4␤2-nAChR
constructs containing zero (LSP or HSP controls), one, or more copies of the ␣4VFL
subunit at the position(s) shown in orange type were used in conjunction with
TEVC to establish and analyze ACh CRCs (see Fig. 6, “Experimental Procedures”).
Pharmacological parameters were determined as described in the legend to Table 1.
Additionally, data representing ACh-activated maximal function (Imax in nA,
rounded to 1 or 2 significant digits) and Imax values corrected for surface nAChR
(microampere/fmol) were generated from (N) experiments testing six individual
oocytes per concatemer per experiment (See Figs. 7 and 8 for these data shown
relative to, and compared with, those obtained from control LSP and HSP concatemers respectively). Number of individual oocytes tested is given as n.
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† One-way ANOVA was used to determine differences across log10 EC50 values
obtained from ␣4VFL-mutant variations on the LSP backbone, as described in
Table 1. All ␣4VFL mutant constructs produced monophasic CRCs, unlike the
biphasic CRC of the parent, unmodified, LSP control. Post hoc comparisons using the Bonferroni correction demonstrated that the log10 EC50 values for all
LSP-backbone ␣4VFL-variant CRCs formed a single group, with lower ACh sensitivity than the HS-phase response of the control construct. Differences from
the HS-phase response are shown as: †, p ⬍ 0.05; ††, p ⬍ 0.01; †††, p ⬍ 0.001. In
contrast, no significant differences were found by ANOVA among log10 EC50
values derived from the universal monophasic responses of the HSP control construct, and ␣4VFL mutant variants thereof. All responses were therefore classified as HS-like.

unaltered ␣4␤2-nAChR LSP control. This loss of per nAChR
function was primarily driven by an ⬃50% loss of Imax, because
changes in surface expression were quite similar across the
range of single, double, and triple ␣4VFL-substituted LSP constructs. As shown in Fig. 7C and Table 2, the loss of function/
nAChR was the same in all three of the double ␣4VFL-substituted LSP constructs. The trend was extended in the case of the
triple ␣4VFL-substituted LSP construct, where a further reduction (to ⬃3% of control) in per receptor function was seen (Fig.
7C and Table 2). In conclusion, function/nAChR effects of
␣4VFL substitution into ␣4␤2-nAChR LSP are position-independent but are copy number-dependent.
This position-independent but copy number-dependent
effect of ␣4VFL substitution was also seen in the ␣4␤2-nAChR
HSP background (Fig. 8). ␣4VFL substitution into either or
both available ␣4 subunit positions suppressed Imax significantly compared with control and reduced nAChR surface
expression by a little over 50% (Fig. 8, A and B). When function
was normalized to a per nAChR basis, the two single-substituted ␣4VFL ␣4␤2-nAChR HSP variants exhibited a similar
not-quite-significant trend to lower function, although the
double-substituted construct produced significantly less function (approximately a 75% reduction; Fig. 8C and Table 2) when
compared with the unmodified ␣4␤2-nAChR HSP construct.
Mutant E-loop Concatenated and Unlinked ␣4␤2-nAChR
Subunit Results Compare Favorably—As shown previously,
␣4␤2-nAChR pentameric and concatemeric constructs can be
expressed without degradation and/or rearrangement of subunit ordering (21, 35, 36). Importantly, these previous studies
demonstrate that concatenated subunit pentameric constructs
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FIGURE 7. ␣4VFL E-loop mutation effects on peak ACh-induced function
(Imax) and nAChR surface expression within LSP concatemers. Oocytes
expressing concatenated LSP constructs incorporating one, two, or three
copies of the ␣4VFL E-loop mutant subunit were screened for maximal ACh
current responses, followed by 125I-mAb 295 binding to determine surface
nAChR expression. All results were normalized to the unmutated LSP concatemer for at least four individual experiments (denoted with a dashed horizontal line in each panel; see Table 2 for the exact number of experiments
performed in each case). A, Imax was reduced in all seven members of the
␣4VFL mutant series of constructs in a copy-dependent, position-independent manner. Single copies of ␣4VFL reduced function by ⬃50%, double
copies by ⬇90%, and the triple copy variant exhibited a 99% loss of function
versus the unmodified LSP control. B, surface nAChR expression levels were
reduced 50 – 80% in all seven of the LSP ␣4VFL mutants independent of position or copy number. C, function per surface nAChR retained copy dependence and position independence for all mutant constructs as in A. ␣4VFL
single copy constructs had WT levels of LSP function; double copies saw a
50% drop in function, and the triple mutant lost 97% of its per receptor function. One-way ANOVA was performed as described in the legend to Fig. 4 and
determined that significant differences existed between groups in each
panel. Post hoc comparisons were made using the Bonferroni correction; differences from the unmutated LSP control are noted as follows: *, p ⬍ 0.05; **,
p ⬍ 0.01; ***, p ⬍ 0.001.
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TABLE 3
E-loop mutation effects on ACh-mediated function in unlinked HS and
LS ␣4␤2 nAChR isoforms

Oocytes were injected with biased ratios of RNA encoding unlinked wt, ␣4VFL, or
␤2HQT subunits to generate predominantly HS (␣4)2(␤2)3- or LS (␣4)3(␤2)2nAChR isoforms (see “Experimental Procedures” for details). ACh-activated Imax
and CRC log10 (M) EC50 values collected in this study are shown in regular font.
Previously published (34) injection ratios and pharmacological parameters generated from nAChR containing the indicated wt or E-loop mutant subunits are shown
(in parentheses and italicized) for comparison, where possible; ND ⫽ not determined. Numbers of oocytes tested are shown for both our, and the previouslypublished, results.

b

FIGURE 8. ␣4VFL E-loop mutation effects on peak ACh-induced function
(Imax) and nAChR surface expression within HSP concatemers. Oocytes
expressing concatenated HSP constructs incorporating one or two copies of
the ␣4VFL E-loop mutant subunit were screened for maximal ACh current
responses, followed by 125I-mAb 295 binding to determine surface nAChR
expression. All results were normalized to the unmutated HSP concatemer for
at least three individual experiments (denoted with a dashed horizontal line in
each panel; see Table 2 for the exact number of experiments performed
in each case). A, Imax was reduced in all three of the ␣4VFL mutant constructs
in a copy-dependent, position-independent manner with both single copies
reduced ⬃75%, and the double copy showed a 95% functional loss versus the
HSP control. B, surface nAChR expression levels were reduced 60 –75% in all
three of the HSP ␣4VFL mutants. C, function per surface nAChR retained copy
dependence and position independence for all mutant constructs as in A.
Both ␣4VFL single copy constructs had similar reductions of function per
receptor but did not quite reach statistical significance versus the level of
non-mutated HSP function. The double copy variant saw a significant ⬇75%
drop in function. One-way ANOVA was performed as described in the legend
to Fig. 5 and determined that significant differences existed between groups
in each panel. Post hoc comparisons were made using the Bonferroni correction; differences from the unmutated LSP control are noted as follows: *, p ⬍
0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001.

are capable of accurately replicating the salient functional pharmacological features of HS and LS ␣4␤2-nAChR isoforms. To
test this point further, we compared results from the concateJANUARY 29, 2016 • VOLUME 291 • NUMBER 5

meric constructs used in this study to those obtained using
unlinked ␣4 and ␤2 subunits. This was done using wild-type ␣4
and ␤2 subunits, and ␤2HQT and ␣4VFL mutant subunits,
injected at ratios known to favor formation of HS or LS ␣4␤2nAChR isoforms. Further comparisons were made to previously published results using these mutant subunits (34).
Where subunit compositions were comparable, the results
remained extremely similar to each other across our concatemeric (Tables 1 and 2) and our unlinked nAChR subunit experiments (Table 3). Both levels of functional expression and ACh
sensitivities match previous findings by others and for receptors of like construction whether from linked or unlinked
subunits.
Mutant E-loop Effects on ␣4␤2-nAChR CRCs Are Similar
between ACh and Nicotine—To determine whether the effects
of E-loop mutations on ACh potency were unique, or whether
they might be more generalizable, we performed an equivalent
set of CRC experiments for nicotine (Fig. 9 and Table 4).
Although nicotine is less discriminating between HS and LS
phase function than ACh (24), very similar outcomes were
clearly visible (compare outcomes in Fig. 9 to those in Figs. 2
and 6). Mutant constructs that exhibited increased ACh
potency also showed increased nicotine potency. Mutant constructs that exhibited decreased ACh potency also did so for
nicotine. Most compellingly, the position-1 ␤2HQT HSP backbone variant showed a significantly shallower Hill slope for nicotine activation and a significantly decreased log10 EC50 value.
These are indicators of a composite CRC containing a new nicotine-evoked response component with lower nicotine sensitivity compared with the parent construct (as seen for the same
construct when stimulated with the more HS versus LS phasediscriminating agonists ACh and A-85380 (Figs. 2 and 3).
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Extra sum-of-squares F-test indicates a preferred biphasic fit: F5,54 ⫽ 11.8; p ⬍
0.0001.
The concatenated version of this all-position-mutated HS isoform had an Imax of
6 ⫾ 1 nA (n ⫽ 22) and an ACh CRC (log10 M) EC50 ⫽ ⫺3.98 ⫾ 0.01 (n ⫽ 10).
c
The concatenated version of this all-position-mutated LS isoform was
non-functional.
a
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Discussion
Major Findings, Differential Functional Effects of Mutating
Nominally Identical ␣4(⫹)/(⫺)␤2 Agonist Binding Pockets;
Dependence on HSP Versus LSP Background—In a pioneering
study, it was first noted explicitly that LS isoform ␣4␤2-nAChR
produce a small proportion of intrinsic HS-like function (34).
Our subsequent finding was that this fraction of HS phase function produced by the LS isoform was similar in terms of function per receptor to the entire response of HS isoform ␣4␤2nAChR (36). These data suggested that HS phase function in
both ␣4␤2-nAChR isoforms may be produced by activation of
the pair of ␣4(⫹)/(⫺)␤2 interfaces common to each isoform.
This concept was reinforced by two further observations (36).
First, HS phase function could be selectively eliminated by predesensitization with the strongly HS activation-preferring
compounds sazetidine-A and A-85380. Second, mutations at
the ␣4(⫹)/(⫺)␣4 site of LS isoform ␣4␤2-nAChR preferentially
reduced LS phase function. However, both these studies, and a
further one reinforcing the importance of ␣4(⫹)/(⫺)␣4 site
engagement for effective activation of LS isoform ␣4␤2-nAChR
(37) implicitly treated the two ␣4(⫹)/(⫺)␤2 agonist-binding
sites as an equivalent pair.
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As outlined in the Introduction, our hypothesis stated that
the two canonical agonist-binding sites might contribute differentially to activation (both within each isoform and between
the two isoforms). This possibility arises because the environments in which the agonist sites are found are not identical;
subunits that contribute the ␣4(⫹)/(⫺)␤2 agonist-binding sites
are surrounded by different neighbors. Please note that because
our experiments with ACh and nicotine both produced very
similar outcomes, we will henceforth predominantly discuss
only our data obtained with ACh, for the sake of clarity. An
overview of our major findings is presented in Fig. 10. It illustrates that insertion of the E-loop ␤2HQT mutant at one or the
other of the two apparently equivalent ␣4(⫹)/(⫺)␤2 agonistbinding sites in the HS ␣4␤2-nAChR isoform produces different changes in ACh sensitivity and/or levels of function per
surface nAChR. We also demonstrate that nominally identical
changes made at the same ␣4(⫹)/(⫺)␤2 interfaces in the LS
␣4␤2-nAChR isoform give markedly different functional outcomes from those seen on the HS isoform background. We
conclude that the two conserved ␣4(⫹)/(⫺)␤2 agonist-binding
sites contribute differently to HS ␣4␤2-nAChR isoform function and between LS and HS ␣4␤2-nAChR isoforms.
VOLUME 291 • NUMBER 5 • JANUARY 29, 2016
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FIGURE 9. Nicotine concentration-response profiles for the ␤2HQT and ␣4VFL E-loop mutant series of concatenated LS and HS ␣4␤2-nAChR isoforms.
Oocytes expressing concatenated LSP (A) or HSP (B) constructs incorporating one or more copies of the ␤2HQT E-loop mutant subunit (position(s) indicated by
␤2m) were acutely stimulated with the indicated range of nicotine concentrations. Responses were normalized to the maximum current measured for each
individual oocyte. Corresponding CRC data are shown for concatenated LSP (C) or HSP (D) constructs incorporating one or more copies of the ␣4VFL E-loop
mutant subunit (position(s) indicated by ␣4m). Details of the obtained pharmacological parameters and the statistical analysis used to compare results are
provided in Table 4. Data points represent the mean (⫾S.E.) of at least six oocytes (numbers provided in Table 4). CRCs obtained using wild-type LSP (f) and
HSP (‚) parent constructs are included in both graphs for ease of comparison within and between isoforms.
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TABLE 4
Effects of introducing ␤2HQT or ␣4VFL E-loop mutant subunits into
the LSP and HSP ␣4␤2 nAChR concatemer backgrounds (nicotine
CRCs)
Oocytes injected with RNA encoding concatenated LSP or HSP ␣4␤2-nAChR constructs containing zero (LSP or HSP controls), one, or more copies of the ␤2HQT or
␣4VFL subunits at the position(s) shown in blue or orange type, respectively, were
used in conjunction with two-electrode voltage clamp to establish and analyze nicotine CRCs (see Fig. 9, “Experimental Procedures”). Pharmacological parameters
were determined as previously described for ACh, and are presented as means ⫾
S.E. Numbers of oocytes tested for each parent construct or variant are indicated,
and data were collected across three biological replicates. Because nicotine is less
discriminating than ACh, none of the CRCs could be fit using a two-site model (fits
would not converge). Accordingly, single-site fits were applied to data from all
constructs. The resulting Hill slope values were uniformly close to 1, with the exception of HSP ␤2HQT position 1 (0.73 ⫾ 0.09 versus. 1.06 ⫾ 0.10 for unmodified HSP;
p ⫽ 0.037 by Student’s t test).

Introduction of ␤2HQT subunits has been proved to alter
agonist binding at ␣4(⫹)/(⫺)␤2 interfaces, making it resemble
more closely binding at an ␣4(⫹)/(⫺)␣4 site (34, 38). In this
study, placement of ␤2HQT mutant subunits into the (⫺)-side
of the conserved canonical ␣4(⫹)/(⫺)␤2 agonist binding interfaces produced very similar outcomes in the LSP (␣4)3(␤2)2
isoform. For example, ␤2HQT insertion into either possible
position produced indistinguishable changes in agonist pharmacology and per receptor function. These outcomes indicate
that, in partial contradiction of our original hypothesis, the two
canonical ␣4(⫹)/(⫺)␤2 agonist-binding sites within the LS isoform ␣4␤2-nAChR likely contribute in similar ways to receptor
activation.
However, the same is not true in the context of the HS isoform. Here, ␤2HQT insertion into the first versus the second
concatemeric ␣4(⫹)/(⫺)␤2 agonist binding interface resulted
in dramatically different ACh CRC outcomes. Effects on per
receptor function also differed considerably between these two
singly substituted HSP mutants. These results are the first demonstration that, despite the fact that the composition of these
canonical ␣4(⫹)/(⫺)␤2 agonist-binding sites is completely
conserved, they make significantly different contributions to
HS isoform ␣4␤2-nAChR activation. This finding is in marked
contrast to the position-independent situation in LS isoform
␣4␤2-nAChR (Fig. 10). Together, these two outcomes confirm
our original hypothesis.
Effects of ␣4VFL Mutant Subunit Introduction, Position and
Background Independence—The HSP-␣4␤2-nAChR construct
contains no ␣4(⫹)/(⫺)␣4 interfaces, so no direct effect would
JANUARY 29, 2016 • VOLUME 291 • NUMBER 5
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**** One-way ANOVA was used to determine differences across log10 EC50 values
obtained from ␤2HQT and ␣4VFL mutant variations on the HSP and LSP backbones (F11,74 ⫽ 113.2, p ⬍ 0.0001, and F11,73 ⫽ 127.5, p ⬍ 0.0001, respectively).
Post hoc comparisons using the Bonferroni correction were used to identify variant constructs with significantly different log10 EC50 values compared to those
calculated for their parent HSP or LSP backbone constructs.

be anticipated on agonist binding following introduction of the
E-loop ␣4VFL mutation into ␣4(⫺)-interfaces. As shown in Fig.
6B, this expectation was met; CRCs were indistinguishable
across all of the ␣4␤2-HSP constructs. Effects on surface
expression and per receptor function were noted, and
these were symmetrical (Figs. 7, B and C, and 10). Similar trends
were observed for per receptor function.
However, results from the LSP-␣4␤2-nAChR construct family, all members of which do contain an ␣4(⫹)/(⫺)␣4 interface,
were much more surprising. Here, substitution of the ␣4VFL
mutant subunit into any position, or combination of positions,
resulted in an identical outcome (Fig. 6A). Similar to the outcome seen in the ␣4␤2-HSP-nAChR context, LSP per receptor
function was progressively reduced as the number of ␣4VFL
mutant subunits introduced was increased, and no position
dependence was seen (Figs. 7C and 10). These findings are surprising given that the ␣4(⫹)/(⫺)␣4 interface within the ␣4␤2LS-nAChR isoform has been shown directly, by multiple
approaches, to correspond to an agonist-binding site (35, 36).
From these findings, we conclude that ␣4(⫺)-face E-loop contributions to ␣4␤2-nAChR function are principally allosteric at
both isoforms (rather than being dominated by direct interactions with ACh at the ␣4(⫹)/(⫺)␣4-binding site, in the context
of the LS isoform). This is not to imply that other parts of the
␣4(⫹)/(⫺)␣4-binding site do not directly interact with ACh or
other agonists; in fact our work and the work of others indicates
that they do (35–37).
Value of Using Tethered nAChR Pentamers and nAChR Cell
Surface Binding Assays—The concatenated nAChR subunit
approach offers substantial advantages in terms of expressing
completely defined nAChR subtypes, including difficult-tocombine subunits (39, 40, 44). It also allows site-directed
mutagenesis to be targeted to particular subunits when multiple copies are present in a pentameric complex (35–37). As
shown in Tables 1–3, functional parameters are very similar
across all comparable nAChR compositions, whether expressed from linked or unlinked subunits. Critically, this validates the utility of concatemeric nAChR as a model in our studies of position-by-position subunit manipulation and our
central discoveries revealed by systematic nAChR subunit
interface alterations.
This study also illustrates the importance of measuring the
effects of subunit mutation on cell surface expression of pure
nAChR populations. Without the ability to normalize for cell
surface nAChR expression, interpretation of differences
between constructs in ion channel function per se would not be
possible.
Although it is certainly true that precise interpretation of
structure-activity relationships using only macroscopic CRCs
can be problematic (48), previously published results allow us to
make predictions. Changes in function per receptor must arise
from altered single-channel conductance and/or open probability. A previous study of HS and LS isoform single-channel
amplitudes indicates that the LS isoform may be associated
with higher calculated chord conductance than the HS isoform
(29 versus 21 picosiemens, respectively (22)). However, this difference is far less than required to account for the difference in
function per receptor for these two isoforms as measured in this
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study (⬃10-fold greater for LS versus HS isoform ␣4␤2nAChR). Accordingly, we predict that the predominant effect
of engaging the ␣4(⫹)/(⫺)␣4 allosteric-like site is to increase
channel-open probability. This would certainly be compatible
with other prior findings. For example, it has been demonstrated that binding to the ␣4(⫹)/(⫺)␣4 site is required for full
agonist efficacy at LS isoform ␣4␤2-nAChR (37). Furthermore,
different parts of the same interface are known to form an allosteric Zn2⫹ potentiation site (49), and it has been shown that the
principal effect of Zn2⫹ potentiation on ␣4␤4-nAChR is to
increase burst duration and therefore open probability (50).
Therefore, it seems reasonable to hypothesize that altered open
probabilities will also be the predominant factor driving the
often large changes in per receptor function that are induced by
incorporation of E-loop mutant subunits. This is especially so
because E-loop mutations are located far from the channel
domain; direct effects on channel conductance would not be
anticipated.
General Rules, Broad Contributions of Particular Subunit
Interfaces to ␣4␤2-nAChR Function—Some generalizable features are revealed by viewing our findings first in terms of alterations in agonist-recognizing subunit interfaces. Nearly every
time that an ␣4(⫹)/(⫺)␤2 interface is converted to a mock
␣4(⫹)/(⫺)␣4 interface, the result is an nAChR with LS-like
features (EC50 value ⱖ60 M). Conversely, there is never an LS
profile for sensitivity to ACh when a natural ␣4(⫹)/(⫺)␣4
interface is eliminated in the LSP backbone. These observations
confirm and extend previous findings indicating that introduc-
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tion of ␤2HQT subunits at ␣4(⫹)/(⫺)␤2 interfaces makes them
more closely resemble ␣4(⫹)/(⫺)␣4 sites with lower ACh sensitivity (34, 38) and that ␣4(⫹)/(⫺)␤2 interfaces contribute to
higher agonist sensitivity. However, this approach is not sufficient to explain all of the findings of this study. As already discussed, introduction of an ␣4VFL mutant subunit anywhere in
the LS isoform background (not just in the ␣4(⫹)/(⫺)␣4 interface) produces a reduction in ACh EC50. In addition, as will be
discussed next, this agonist-binding-site-only model is not adequate to explain several more observations.
Exceptions to the General Rules, the Importance of Neighbors
and the E-loop—Defining the precisely detailed mechanisms
underlying differential ␣4(⫹)/(⫺)␤2 agonist site contributions
to HS and LS isoform ␣4␤2-nAChR activation (such as changes
in binding site affinity, interactions between the multiple binding sites present, and the extent of site-to-site cooperativity) is
likely to require a sophisticated and extensive single-channel
kinetics analysis, far beyond the scope of this study (48). However, the hypothesis that introducing mutations into the
E-loops of ␣4␤2-nAChR isoforms can significantly alter the
allosteric activation mechanism of the host nAChR could also
apply to ␤2HQT mutant subunits. In fact, this new hypothesis
can explain our further otherwise-surprising observations (in
addition to the position independence of the ␣4VFL subunit’s
effects).
In the first example, only the position 1 ␤2HQT mutant on
an HSP backbone exhibits biphasic ACh activation (Figs. 2B
and 3). This concatemer and the LSP construct are the only
VOLUME 291 • NUMBER 5 • JANUARY 29, 2016
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FIGURE 10. Reciprocal E-loop mutations placed within or outside of ␣4(ⴙ)/(ⴚ)␤2 nAChR agonist binding interfaces reveal intra- and inter-isoform
functional differences. An overview is provided of the major findings generated by employing systematic E-loop substitution in concatenated ␣4␤2-nAChR
isoforms. In the case of the ␤2HQT series of concatemers (center columns), E-loop probing revealed differential functional effects of altering nominally identical
␣4(⫹)/(⫺)␤2-binding sites within the HSP background (outcomes were strongly dependent on position and copy number for EC50 and Imax/nAChR determinations). Contrasting results were seen following ostensibly identical manipulations performed on the LSP background (outcomes were predominantly
position-independent). Conversely, ␣4VFL subunits placed within either isoform (flanking columns) yielded highly similar results in terms of within and
between the HSP and LSP backgrounds. Position and copy independence was observed when considering EC50 values, and position independence and copy
dependence were typical features when considering per receptor function. Because functional changes resulting from introduction of the ␣4VFL mutant
subunit were ␣4(⫹)/(⫺)␣4 interface-independent, they are likely to be predominantly allosteric in nature, rather than driven by a direct E-loop interaction with
agonist at this site.
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seen in other Cys-loop receptors, given the high degree of structural similarity across members of the superfamily.
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ones featuring an ␣4(⫹)/(⫺)␣4-like agonist binding pocket
flanked by unmutated ␤2 subunits (see inset to Fig. 3 for a circularized representation of the assembled position 1 ␤2HQT
HSP construct). In the second example, a single ␤2HQT
mutant-subunit substitution in either position 3 (where it does
participate in an ␣4(⫹)/(⫺)␤2 agonist binding pocket) or position 5 (where it does not participate in an agonist-binding site)
has no effect on the resulting agonist CRCs (Fig. 2B). However,
combining these two mutations, which are individually without
effect, results in a substantial loss of agonist potency. This constitutes direct evidence that the E-loop status of a neighboring
subunit can affect the functional contribution of a canonical
␣4(⫹)/(⫺)␤2 agonist-binding site. It therefore appears that the
functional effects of the ␤2HQT mutation are mediated allosterically in addition to its recently demonstrated effect on agonist binding potency (38). In the third example, and related to
the preceding point, function per nAChR in the HSP ␤2HQT
mutant series (Fig. 5) is significantly reduced only if both
subunits at the ␤2(⫹)/(⫺)␤2 interface are mutated (HSP
␤2HQTp1p5, and ␤2HQTp1p3p5). In addition, on the HSP
backbone, the presence of just one ␣4(⫹)/(⫺)␤2 interface is
adequate to yield HS function except in the presence of
␤2HQTp5 altering the ␤2(⫹)/(⫺)␤2 interface. These observations suggest that a wild-type ␤2(⫹)/(⫺)␤2 interface is an
important factor in HSP function. As a corollary to this
observation, the LSP isoform, which lacks a ␤2(⫹)/(⫺)␤2
interface, loses all HS component function with just one
␤2HQT substitution. Our results imply that E-loop allosteric
effects constitute an important part of the context that
results in otherwise identical ␣4(⫹)/(⫺)␤2 agonist-binding
sites contributing differentially to nAChR agonist activation
both within HS isoform ␣4␤2-nAChR and between the two
␣4␤2-nAChR isoforms.
Interestingly, the current findings dovetail with and also help
to explain observations in other studies (of ␣6␤2*-nAChR) that
pointed to the importance of ␣6 (⫺)-face E-loop effects on
functional levels and agonist sensitivities (51–53). In those publications, mouse (Asp-143 and Val-145) or human (Asn-143
and Met-145) ␣6 subunit residues determined in a species-specific manner functional effects of ␤3 subunit co-assembly into
␣6*-nAChR containing ␤2 or ␤4 subunits. These residues are
nested between the ␣4 and ␤2 subunit E-loop residues that
were targeted in this study. A very recent publication (54) also
demonstrated interactions of an ␣4 (⫺)-face E-loop engineered
into the binding pocket of Lymnaea stagnalis acetylcholinebinding protein with a neighboring subunit. These interactions
differed according to which particular ligand was bound (at
least for compounds that are exceptionally selective between
HS and LS phase activation), and appeared likely to impact
receptor activation (54). If somewhat analogous interactions
occur at interfaces not bound by agonist, this may provide at
least a partial mechanistic basis for E-loop involvement in the
neighbor effects noted in this study.
Our findings illustrate previously unappreciated complexity
in the agonist activation mechanism of ␣4␤2-nAChR, which
are a predominant and physiologically important non-muscle
nAChR subtype. It seems likely that similar phenomena may be
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